Informations

Histone deacetylases (HDACs) are histone-modifying enzymes that play a key role in regulating epigenetic changes, and they are closely linked to the development and drug resistance of breast cancer. HDAC inhibitors (HDACis) can selectively modulate epigenetic features to control tumor cell proliferation, regulate the cell cycle, and repair DNA damage. As a representative class of…

The normalization of epigenetic regulation has emerged as a promising therapeutic strategy in oncology. In hormone receptor-positive (HR⁺) breast cancer, the highly selective HDAC inhibitor (HDACi) entinostat has shown the ability to induce cell cycle arrest and apoptosis in multidrug-resistant tumor cells, addressing resistance to endocrine and targeted therapies at the mechanistic level. Moreover, a…

Whether anthracyclines are essential in the neoadjuvant chemotherapy of HER2-positive breast cancer remains a long-debated question. The BCIRG-006 study suggested that anthracycline-containing and anthracycline-free regimens yielded numerically comparable survival outcomes, while the anthracycline-free TCbH regimen demonstrated a lower incidence of congestive heart failure and cardiac dysfunction. However, direct head-to-head comparisons between the two strategies are…

Breast cancer remains the most frequently diagnosed cancer among women worldwide, and the pursuit of novel therapies continues to command global attention. In the setting of HR+/HER2− advanced breast cancer, the introduction of entinostat, a novel histone deacetylase inhibitor (HDACi), marks a significant therapeutic advancement. With a distinctive mechanism of action, entinostat not only extends…

As treatment options for hormone receptor-positive (HR⁺) breast cancer continue to diversify—from chemotherapy and endocrine therapy to targeted treatments—survival outcomes are improving. However, alongside extended survival, maintaining quality of life (QoL) and enabling patients to return to everyday life have become equally vital goals. Entinostat, a novel histone deacetylase inhibitor (HDACi), stands out with its…

Hormone receptor-positive (HR+) breast cancer accounts for approximately 70% of all breast cancer cases and remains the most prevalent subtype. While endocrine therapy continues to serve as the cornerstone of HR+ breast cancer treatment, and CDK4/6 inhibitors (CDK4/6i) have become standard in both early and advanced settings, resistance to therapy remains a formidable clinical challenge.…

Breast cancer remains one of the leading malignancies threatening women’s health worldwide. Among its various subtypes, hormone receptor-positive (HR⁺) breast cancer is the most prevalent, comprising about 70% of all cases. While the advent of CDK4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) has become the gold standard for first-line treatment of HR⁺/HER2⁻ advanced breast…

With the continuous advancement of pharmaceutical and medical technologies, novel therapies have steadily extended survival for breast cancer patients. Among them, the combination of CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) has brought transformative improvements in outcomes for patients with hormone receptor-positive/HER2-negative (HR+/HER2−) metastatic breast cancer (MBC). Despite its establishment as the current standard first-line…